S

Shionogi & Co Ltd
TSE:4507

Watchlist Manager
Shionogi & Co Ltd
TSE:4507
Watchlist
Price: 2 210.5 JPY -0.05% Market Closed
Market Cap: 2T JPY
Have any thoughts about
Shionogi & Co Ltd?
Write Note

Shionogi & Co Ltd
PP&E Net

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shionogi & Co Ltd
PP&E Net Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company PP&E Net CAGR 3Y CAGR 5Y CAGR 10Y
S
Shionogi & Co Ltd
TSE:4507
PP&E Net
ÂĄ121.1B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
4%
Takeda Pharmaceutical Co Ltd
TSE:4502
PP&E Net
ÂĄ1.9T
CAGR 3-Years
9%
CAGR 5-Years
5%
CAGR 10-Years
13%
Daiichi Sankyo Co Ltd
TSE:4568
PP&E Net
ÂĄ458.4B
CAGR 3-Years
17%
CAGR 5-Years
14%
CAGR 10-Years
4%
Otsuka Holdings Co Ltd
TSE:4578
PP&E Net
ÂĄ578.8B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
PP&E Net
ÂĄ426.4B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
12%
Astellas Pharma Inc
TSE:4503
PP&E Net
ÂĄ315.3B
CAGR 3-Years
6%
CAGR 5-Years
4%
CAGR 10-Years
5%
No Stocks Found

Shionogi & Co Ltd
Glance View

Market Cap
1.9T JPY
Industry
Pharmaceuticals

In the bustling landscape of pharmaceuticals, Shionogi & Co., Ltd. emerges as a distinguished player with a rich legacy rooted in over a century of innovation and meticulous craftsmanship. Founded in 1878, this Japanese pharmaceutical stalwart has strategically steered its trajectory toward addressing unmet medical needs through research-driven innovation. Shionogi's core strength lies in its research and development capabilities, focusing predominantly on infectious diseases, pain therapeutics, and chronic conditions such as cardiovascular diseases and diabetes. This dedication is evident in their robust pipeline and successful launch of drugs like Fetroja—an antibiotic that fights resistant bacterial infections—and Xofluza, a novel anti-influenza medication. By continually investing in and prioritizing R&D, Shionogi ensures a steady output of groundbreaking treatments that not only embody therapeutic efficacy but also meet stringent safety standards. Financially, Shionogi operates through a strategic blend of innovative product sales and lucrative licensing agreements. As its proprietary medications penetrate global markets, the revenue stream flowing from these products fortifies the company’s economic foundation. Notably, Shionogi nurtures collaborative alliances with international pharmaceutical giants, enhancing its global outreach through mutual licensing agreements and shared drug development initiatives. These alliances not only expand the availability of its drugs worldwide but also provide Shionogi with substantial royalty and milestone payments. Additionally, the company's foray into vaccine production has further diversified its portfolio, as it aims to leverage its technological prowess in response to global health challenges. This intricate balance of direct product sales and strategic alliances powerfully anchors Shionogi's financial stability while paving the way for future innovations.

Intrinsic Value
2 171.28 JPY
Overvaluation 2%
Intrinsic Value
Price
S

See Also

What is Shionogi & Co Ltd's PP&E Net?
PP&E Net
121.1B JPY

Based on the financial report for Sep 30, 2024, Shionogi & Co Ltd's PP&E Net amounts to 121.1B JPY.

What is Shionogi & Co Ltd's PP&E Net growth rate?
PP&E Net CAGR 10Y
4%

Over the last year, the PP&E Net growth was 2%. The average annual PP&E Net growth rates for Shionogi & Co Ltd have been 7% over the past three years , 10% over the past five years , and 4% over the past ten years .

Back to Top